Role of C-Reactive Protein at Sites of Inflammation and Infection

If your body is under attack, it needs an alarm signal — something that can surge a thousandfold in hours and tell the immune system exactly where to go and what to do. So evolution built one. It's called C-reactive protein, or CRP. For decades, doctors used it as a passive thermometer of disease — a number in a blood test that confirmed something was wrong. The review by Sproston and Ashworth argues that picture is incomplete. CRP isn't just measuring inflammation. In important ways, it's making it. Start with the molecule itself. In its circulating form, CRP is a homopentamer — five identical protein subunits locked together in a discoid ring, like five pieces of a puzzle arranged around a central pore. Each subunit is 206 amino acids long, roughly 23 kilodaltons in mass, and presents a binding site for phosphocholine on one face — the face that recognizes targets like bacterial cell walls. The opposite face interacts with immune components. Each subunit also binds two calcium ions, which are required for stable ligand binding. This pentameric form is called native CRP, or nCRP. The liver makes most of it. Hepatocytes ramp up CRP production in response to inflammatory cytokines, especially interleukin-6, with interleukin-1 and tumor necrosis factor alpha playing supporting roles. CRP is also synthesized outside the liver — in smooth muscle cells, macrophages, endothelial cells, lymphocytes, and adipocytes. In a healthy person, circulating CRP averages around 0.8 milligrams per liter. During a severe bacterial infection, it can climb above 500 micrograms per milliliter — that thousandfold surge — within 24 to 72 hours. When the threat resolves, CRP falls with a half-life of roughly 18 to 20 hours. Now here is where the story gets interesting. CRP is not one molecule. It's two. At sites of inflammation and tissue damage, native CRP can irreversibly dissociate into five separate monomers. This form is called monomeric CRP, or mCRP. The dissociation is not reversible — once it happens, you cannot reconstitute the pentamer. It can occur when nCRP binds to cell membranes, passing through a membrane-bound intermediate before the monomers fully detach. The two isoforms differ antigenically, biologically, and in how they behave under electrophoresis. They expose different surface regions and bind different receptors. This distinction helps explain why early CRP literature is often contradictory. Studies would report simply "CRP" without specifying which form was used or measured. Commercial antibodies specific to mCRP are not widely available, so relatively few labs could study the monomeric isoform at all. The result, as Sproston and Ashworth describe it, is a field that spent decades studying what it thought was one molecule when it was actually looking at two, with opposing tendencies. So what does each form actually do? Native CRP, the pentamer, functions primarily as a resolver. It finds threats, promotes their removal, and helps shut down the immune response. Its first major action is activating the classical complement pathway — complement being the immune system's fast-acting chemical artillery. When nCRP binds to phosphocholine determinants on bacterial surfaces, the opposite face of the pentamer recruits C1q and triggers the early classical components: C1, C4, and C2, leading to C3 convertase formation. Critically, this process does not progress far down the complement cascade. nCRP also recruits factor H, which inhibits the alternative complement pathway and suppresses the terminal membrane attack complex. The result is targeted early activation without collateral tissue destruction. nCRP also promotes phagocytosis. It opsonizes pathogens — essentially flagging them for destruction by coating them so immune cells can recognize and engulf them. In one experimental model cited by Sproston and Ashworth, mice pretreated with 200 micrograms of CRP showed markedly improved survival across a range of pathogen doses. This opsonization works both through complement activation and through direct engagement with Fc gamma receptors on leukocytes. And nCRP promotes apoptosis — programmed cell death — in damaged host cells. It binds apoptotic cells, inhibits terminal complement assembly on their surfaces, and opsonizes them for Fc gamma receptor-mediated phagocytosis. Through receptors including Fc gamma receptor IIa and Fc gamma receptor I, nCRP has been linked to upregulation of the p53 protein in monocytes and induction of G2 to M cell-cycle arrest and caspase-dependent apoptosis in vascular cells. In short, nCRP is the anti-inflammatory isoform: find the threat, clear it, clean up the mess. Monomeric CRP does the opposite. Rather than resolving inflammation, mCRP amplifies it. Once deposited in inflamed tissue — mCRP is insoluble in plasma and localizes at the site — it begins recruiting more immune cells. It stimulates production of monocyte chemoattractant protein-1, or MCP-1, with MCP-1 messenger RNA rising within 2 hours of exposure and remaining elevated for at least 24 hours. mCRP acts as a direct chemoattractant for monocytes and upregulates interleukin-8 production through a p38 MAPK-dependent mechanism — p38 MAPK being a key intracellular signaling enzyme in inflammatory cascades. Blocking CD16, the receptor Fc gamma receptor IIIb, inhibited mCRP-stimulated nitric oxide formation and interleukin-8 release, pinpointing the receptor responsible for much of this signaling. On cell survival, the two isoforms again pull in opposite directions. nCRP promotes apoptosis, clearing damaged cells from the site. mCRP delays apoptosis by triggering cell-survival pathways in neutrophils, sustaining their presence at the inflamed focus. For nitric oxide, nCRP attenuates production by downregulating endothelial nitric oxide synthase, while mCRP enhances it in neutrophils through calcium mobilization and phosphoinositide 3-kinase signaling. Same protein origin, same inflamed tissue — but after dissociation, mCRP becomes the amplifier, not the resolver. This contrast becomes clinically urgent in the context of cardiovascular disease, where most CRP research has been concentrated. Sproston and Ashworth detail how CRP actively drives the arterial inflammation that underlies atherosclerosis. CRP stimulates endothelial cells to produce MCP-1, upregulates the monocyte chemotaxis receptor CCR2, and draws monocytes into vessel walls. The mCRP isoform is specifically implicated here: incubation with mCRP increases MCP-1 secretion through that same p38 MAPK mechanism, while nCRP had no detectable effect in the same model. CRP also interacts with oxidized LDL — the modified form of cholesterol that accumulates in arterial plaques — in ways that alter macrophage cytokine responses, including changes in tumor necrosis factor alpha and interleukin-6. A circulating CRP level above 3 milligrams per liter is associated with increased coronary heart disease risk, and the molecular picture suggests that association may be partly causal, not merely correlational. That clinical interpretation is further complicated by hormone therapy. In elderly women receiving oral postmenopausal hormone replacement therapy, background circulating CRP rises. Transdermal estrogen appears to have little effect or may reduce CRP levels. This means elevated CRP in certain patient populations could reflect both vascular inflammation and a treatment effect — a confound that matters when CRP is being used to assess cardiovascular risk. Sproston and Ashworth are careful about what remains unknown. Most CRP research has focused on vascular disease and stroke. The roles of CRP isoforms in peripheral tissues — skin, for example — remain underexplored. And because mCRP-specific antibodies are not commercially available, the monomeric isoform has been studied by relatively few laboratories. The question the review implicitly raises is a therapeutic one. If nCRP and mCRP exert opposing effects at the same site of inflammation, could selectively targeting one isoform become a treatment strategy? Preventing nCRP from dissociating into mCRP, or specifically inhibiting mCRP's pro-inflammatory actions, could in principle interrupt the amplification loop without disrupting the resolution functions of the native form. Sproston and Ashworth cite such approaches as proposals requiring much more isoform-specific investigation before any clinical application. What the review establishes clearly enough is this: the field has been studying one molecule when it should have been studying two. nCRP resolves inflammation — it activates complement early, promotes phagocytosis, and clears damaged cells. mCRP amplifies it — it recruits leukocytes, delays their death, and drives pro-inflammatory mediators. They share a gene, a synthesis site, and an initial structure. What separates them is where they end up and what happens when they get there. A blood test that measures total CRP collapses that distinction entirely. The number on the lab report, it turns out, is the beginning of the question — not the answer. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.